Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,895 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer LJV', Esserman L, Rugo HS. Huppert LA, et al. Among authors: thomas a. Ann Oncol. 2024 Oct 28:S0923-7534(24)04070-5. doi: 10.1016/j.annonc.2024.10.018. Online ahead of print. Ann Oncol. 2024. PMID: 39477071
Germline EGFR Mutations and Familial Lung Cancer.
Oxnard GR, Chen R, Pharr JC, Koeller DR, Bertram AA, Dahlberg SE, Rainville I, Shane-Carson K, Taylor KA, Sable-Hunt A, Sholl LM, Teerlink CC, Thomas A, Cannon-Albright LA, Fay AP, Ashton-Prolla P, Yang H, Salvatore MM, Addario BJ, Jänne PA, Carbone DP, Wiesner GL, Garber JE. Oxnard GR, et al. Among authors: thomas a. J Clin Oncol. 2023 Dec 1;41(34):5274-5284. doi: 10.1200/JCO.23.01372. Epub 2023 Oct 23. J Clin Oncol. 2023. PMID: 37579253
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, Burns S, Marsh L, Vyas P, Metzner M, McCarthy N, Andrew G, Byrne J, Sellar RS, Kelly R, Cahalin P, Overgaard UM, Mehta P, Dennis M, Knapper S, Freeman SD. Russell NH, et al. J Clin Oncol. 2024 Nov 18:JCO2400259. doi: 10.1200/JCO.24.00259. Online ahead of print. J Clin Oncol. 2024. PMID: 39556780
Toward a common interpretation of the 3Rs principles in animal research.
Lauwereyns J, Bajramovic J, Bert B, Camenzind S, De Kock J, Elezović A, Erden S, Gonzalez-Uarquin F, Ulman YI, Hoffmann OI, Kitsara M, Kostomitsopoulos N, Neuhaus W, Petit-Demouliere B, Pollo S, Riso B, Schober S, Sotiropoulos A, Thomas A, Vitale A, Wilflingseder D, Ahluwalia A. Lauwereyns J, et al. Lab Anim (NY). 2024 Nov 15. doi: 10.1038/s41684-024-01476-2. Online ahead of print. Lab Anim (NY). 2024. PMID: 39548348 No abstract available.
Sequence modeling and design from molecular to genome scale with Evo.
Nguyen E, Poli M, Durrant MG, Kang B, Katrekar D, Li DB, Bartie LJ, Thomas AW, King SH, Brixi G, Sullivan J, Ng MY, Lewis A, Lou A, Ermon S, Baccus SA, Hernandez-Boussard T, Ré C, Hsu PD, Hie BL. Nguyen E, et al. Science. 2024 Nov 15;386(6723):eado9336. doi: 10.1126/science.ado9336. Epub 2024 Nov 15. Science. 2024. PMID: 39541441
9,895 results